Nabilone

Nabilone

SCHEMBL15520922

CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)C1CCC(=O)C[C@@H]21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CNR1

The experimentally established mechanism targets of Nabilone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CNR1 known ✓ P21554 12/20 1.00
CNR2 P34972 14/20 1.00
NR1I2 O75469 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
SLC6A3 Q01959 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nabilone SCHEMBL33339 1.00 CNR2 (1.00) CNR2CNR1NR1I2ADORA3SLC6A3
Nabilone SCHEMBL17223864 1.00 CNR2 (1.00) CNR2CNR1NR1I2ADORA3SLC6A3
Nabilone SCHEMBL29475614 1.00 CNR2 (1.00) CNR2CNR1NR1I2ADORA3SLC6A3
Nabilone SCHEMBL11268571 1.00 CNR2 (1.00) CNR2CNR1NR1I2ADORA3SLC6A3
Nabilone SCHEMBL2762240 1.00 CNR2 (1.00) CNR2CNR1NR1I2ADORA3SLC6A3
Nabilone SCHEMBL563809 1.00 CNR2 (1.00) CNR2CNR1NR1I2ADORA3SLC6A3
Nabilone SCHEMBL13759779 1.00 CNR2 (1.00) CNR2CNR1NR1I2ADORA3SLC6A3
SCHEMBL11615666 1.00 CNR2 (1.00) CNR2CNR1NR1I2ADORA3SLC6A3
Nabilone SCHEMBL29448222 1.00 CNR2 (1.00) CNR2CNR1NR1I2ADORA3SLC6A3
SCHEMBL11615083 0.99 CNR2 (0.98) CNR2CNR1NR1I2ADORA3SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964956-B2 Cannabinergic compounds and uses thereof NORTHEASTERN UNIVERSITY (US) 2024-04-23 US disclosed
EP-3840852-B1 PROCESS FOR THE PRODUCTION OF CANNABINOIDS BESSOR PHARMA LLC (US) 2023-10-04 EP disclosed
US-20230241085-A1 CANNABINOID AND SUGAR ALCOHOL COMPLEX, METHODS TO MAKE AND USE APIRX PHARMACEUTICAL USA, LLC (US) 2023-08-03 US disclosed
US-20200038421-A1 CANNABINOID AND SUGAR ALCOHOL COMPLEX, METHODS TO MAKE AND USE AXIM BIOTECHNOLOGIES, INC 2020-02-06 US disclosed
EP-3528784-A1 SUPPOSITORIES COMPRISING CANNABINOIDS Axim Biotechnologies, Inc. (US) 2019-08-28 EP disclosed
WO-2018075730-A1 SUPPOSITORIES COMPRISING CANNABINOIDS Axim Biotechnologies, Inc. (US) 2018-04-26 WO disclosed
WO-2014039042-A1 NOVEL CANNABINERGIC COMPOUNDS AND USES THEREOF NORTHEASTERN UNIVERSITY (US) 2014-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964956-B2 Cannabinergic compounds and uses thereof CNR2, CNR1, GPR18 CNR1 2/4885CNR2 1/4885NR1I2 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.